Alkem reports record high EBITDA, strong revenue growth in Q4 & FY26
Friday, May 29, 2026
Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the fourth quarter ended March 31, 2026. The Board of Directors took record of these results at its meeting held in Mumbai today.
Q4FY26 Key Financial Metrics
Commenting on the results, Dr. Vikas Gupta, CEO of Alkem, said, “We are pleased to report that Alkem has recorded its highest ever EBIDTA in FY26, reaffirming the strength of our growth strategy, execution and operational rigour. Our top-line growth was broad-based with both domestic branded generics and international business delivering strong growth. An improving business mix, operating leverage and continued cost discipline drove meaningful margin expansion in FY26. Our financial performance in Q4 was also marked by strong revenue and EBITDA growth as well as a significant increase of 40.7% in our profit before tax and exceptional item. We enter FY27 on a firm foundation and expect healthy growth across businesses supported by increasing contribution from chronic therapies and a differentiated launch pipeline for international markets.”
Q4 FY26 Key Financial Highlights
- Total Revenue from Operations was ₹36,033 million, with YoY growth of 14.6%.
- India sales were ₹23,245 million, YoY growth of 8.8%.
- International sales were ₹12,223 million, with YoY growth of 25.4%.
- EBITDA was ₹5,174 million, resulting in an EBITDA margin of 14.4% vs. 12.4% in Q4 FY25. EBITDA grew by 32.2% YoY.
- R&D expenses for Q4 FY26 were ₹2,293 million, or 6.4% of total revenue from operations, vs. ₹1,585 million in Q4 FY25 at 5.0% of total revenue from operations.
- Profit before tax (before exceptional item) was ₹5,578 million, YoY growth of 40.7%.
- Exceptional items for the quarter include ₹602.7 million incremental liability towards gratuity and leave encashment for past service cost following finalisation of Central Rules under the Labour Codes, and ₹747 million impairment of real estate investments.
- Net Profit (after Non-Controlling interest) was ₹2,365 million, YoY de-growth of 22.7%.
FY26 Key Financial Highlights
- Total Revenue from Operations was ₹147,123 million, with YoY growth of 13.5%.
- India sales were ₹98,514 million, YoY growth of 9.7%.
- International sales were ₹46,810 million, with YoY growth of 22.5%.
- EBITDA was ₹30,052 million, resulting in an EBITDA margin of 20.4% vs. 19.4% in FY25. EBITDA grew by 19.6% YoY.
- R&D expenses for FY26 were ₹6,173 million, or 4.2% of total revenue from operations, vs. ₹5,620 million in FY25 at 4.3% of total revenue from operations.
- Profit before tax (after exceptional item) was ₹28,709 million, YoY growth of 13.6%.
- Exceptional items for the year include:
- ₹1,130.6 million liability towards gratuity and leave encashment for past service cost following finalisation of Central Rules under the Labour Codes.
- ₹747 million provision for impairment of real estate investments.
- Partly offset by an exceptional gain of ₹142.9 million from reversal of impairment on sale of the Indore facility.
- Net Profit (after Non-Controlling interest) was ₹23,018 million, YoY growth of 6.3%.
Operational Highlights
Q4 FY26 Domestic Business Key Highlights
- The contribution of domestic sales to total sales was 65.5% vs. 68.7% in Q4 FY25.
- According to IQVIA (SSA) data, for Q4 FY26:
- The Company registered a growth of 11.1% YoY vs Indian Pharmaceutical Market (IPM), which grew by 10.1%, 100 bps outperformance.
- Acute segment reported growth of 10.0% vs IPM which grew by 7.7%, 230 bps outperformance.
- Chronic segment reported growth of 16.1% vs. IPM which grew by 13.6%, 250 bps outperformance.
- We have outperformed IPM in six key focused therapies: Gastro-intestinal grew by ~1.8X, VMN ~1.6X, Pain ~1.7X, Anti-Diabetic ~1.4X, Respiratory ~1.6X and Derma ~2.0X.
FY26 Domestic Business Key Highlights
- The contribution of domestic sales to total sales was 67.8% vs. 70.2% in FY25.
- According to IQVIA (SSA) data, for FY26:
- The Company registered a growth of 9.2% YoY vs Indian Pharmaceutical Market (IPM), which grew by 9.0%, 20 bps outperformance.
- Acute segment reported growth of 8.5% vs IPM which grew by 6.8%, 170 bps outperformance.
- Chronic segment reported growth of 12.6% vs. IPM which grew by 12.5%, 10 bps outperformance.
- We have outperformed IPM in seven key focused therapies: Anti-infectives grew by ~1.1X, Gastro-intestinal ~1.5X, VMN ~2.0X, Pain ~1.6X, Anti-Diabetic ~1.2X, Respiratory ~1.4X and Derma ~1.8X.
Q4FY26 International Business Key Highlights
- US sales were ₹7,681 million, YoY growth of 26.2%.
- US business sales contributed 21.7% to total sales in Q4 FY26 vs. 19.6% in Q4 FY25.
- Non-US sales were ₹4,543 million, YoY growth of 24.1%.
- Non-US business sales contributed 12.8% to total sales in Q4 FY26 vs. 11.8% in Q4 FY25.
- During Q4 FY26, for the US market, the Company filed 05 ANDAs and received 04 ANDAs approvals.
FY26 International Business Key Highlights
- US sales were ₹29,845 million, YoY growth of 20.3%.
- US business sales contributed 20.5% to total sales in FY26 vs. 19.4% in FY25.
- Non-US sales were ₹16,964 million, YoY growth of 27.4%.
- Non-US business sales contributed 11.7% to total sales in FY26 vs. 10.5% in FY25.
- As of March 31, 2026, the Company had filed 192 ANDAs, 02 NDAs and 01 BLA with the USFDA. It has received approvals for 167 ANDAs (including 19 tentative approvals) and 02 NDAs. The Company launched 11 products during FY26.
Facility Regulatory Status
About Alkem: Alkem Laboratories Ltd. is the sixth - largest pharmaceutical company in the Indian market, with a legacy spanning over 50 years of providing high-quality medicines to patients. It holds a dominant position in the therapy areas of anti-infectives, gastrointestinal disorders, pain management, and supplements. It also has a growing portfolio of products in chronic therapies, including diabetes, neurology, dermatology, and urology. It has 18 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia, and several other Asian countries. “Inspiring Healthier Lives” is at the core of the organization’s values and culture, reinforcing its steadfast commitment to improving global health. For more information, please visit www.alkemlabs.com and follow us on LinkedIn, Instagram, and Facebook.
Contact
Investors:
Purvi Shah – Head of Investor Relations
+91 84337 00890
purvi.shah@alkem.com
+91-22-3982 9999 Ext: 9447
Media:
Isha Trivedi
+91 98925 90003
alkemcorpcomm@alkem.com
+91-22-3982 9999 Ext:9672
Invite for Q4FY26 & FY26 Conference Call at 4.30 pm IST, May 28, 2026
Mumbai, May 20, 2026: Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Thursday, May 28, 2026, from 4:30 pm to 5:30 pm IST to discuss its Q4 and FY26 financial results. The call will follow the announcement of the Company’s Q4 and FY26 financial results on Thursday, May 28, 2026.
Alkem Laboratories Ltd. will be represented on the call by:
Mr. Sandeep Singh - MD
Dr. Vikas Gupta – CEO, Alkem Laboratories
Mr. Nitin Agrawal – CFO
Motilal Oswal Securities Ltd will host the call.
4:30 pm IST (GMT + 5:30) on Thursday, May 28, 2026.
Dial in Details
India:+91 22 6280 1149 / +91 22 7115 8050
International Toll-Free
USA 1 866 746 2133
UK 0 808 101 1573
Singapore 800 101 2045
Hong Kong 800 964 448
Express Join with Diamond Pass
Purvi Shah / Isha Trivedi
Investor Relations / Media Alkem Laboratories Ltd.
Mobile: +91 84337 00890 / 98925 90003
Tel.: +91 22 3982 9999 Ext: 9447
E-mail: purvi.shah@alkem.com/ isha.trivedi@alkem.com
Tushar Manudhane
Institutional Research Analyst - Healthcare Motilal Oswal Securities Ltd.
Tel.: +91 22 6129 1536 / +91 82911 38039
E-mail: Tushar.Manudhane@motilaloswal.com
